search icon

    Market Snapshot

    • S&P Futures

      3,809.5

    • Dow Futures

      30,868

    • Nasdaq Futures

      11,633.25

    blog search icon

    Aligos Therapeutics, Inc.

    (NASDAQ:ALGS)

    $1.21

    $-0.06

    -4.72%

    Aligos Therapeutics, Inc. Chart

    ALGS Stock Price Today

    Aligos Therapeutics, Inc. (ALGS) stock declined over -4.72% intraday to trade at $1.21 a share on NASDAQ. The stock opened with a loss of -9.70% at $1.25 and touched an intraday high of $1.27, falling -4.72% against the last close of $1.27. The stock went to a low of $1.2 during the session.

    Stock Snapshot

    $1.27

    Prev. Close

    52.83 Million

    Market Cap

    $1.2

    Day Low

    $1.25

    Open

    42.51 Million

    Number of Shares

    $1.27

    Day High

    -

    P/E ratio

    -3.31

    EPS (TTM)

    4.47

    Cash Flow per Share

    8.97

    Free Float in %

    5.09

    Book Value

    94,152

    Volume

    Aligos Therapeutics, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-06-30$1.25$1.27$1.2$1.2190,745
    2022-06-29$1.34$1.34$1.23$1.27125,700
    2022-06-28$1.35$1.42$1.26$1.3180,700
    2022-06-27$1.3$1.42$1.21$1.35186,400
    2022-06-24$1.38$1.38$1.28$1.312,388,900
    2022-06-23$1.22$1.34$1.22$1.34272,700
    2022-06-22$1.17$1.27$1.17$1.21242,700
    2022-06-21$1.17$1.19$1.13$1.19238,600
    2022-06-17$1.21$1.25$1.11$1.11442,000
    2022-06-16$1.29$1.295$1.2$1.21134,500

    Contact Details

    One Corporate Drive
    2nd Floor
    South San Francisco, CA 94080
    United States

    Webiste:ALGS

    800 466 6059

    Company Information

    Employees-

    Beta-

    Sales or Revenue4.36 Million

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

    Frequently Asked Questions

    icon

    What is the current Aligos Therapeutics, Inc. (ALGS) stock price?

    Aligos Therapeutics, Inc. (NASDAQ: ALGS) stock price is $1.21 as of the last check on Thursday, June 30. During the trading session, ALGS stock reached the peak price of $1.27 while $1.2 was the lowest point it dropped to.

    icon

    ALGS's industry and sector of operation?

    The NASDAQ listed ALGS is part of Biotechnology industry that operates in the broader Health Care sector. Aligos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.

    icon

    Who are the executives of ALGS?

    Dr. Lawrence M. Blatt MBA, Ph.D.
    CEO & Chairman
    Dr. Leonid Beigelman Ph.D.
    Pres & Director
    Dr. Julian A. Symons DPHIL
    Exec. VP & Chief Scientific Officer
    Ms. Lesley Ann Calhoun CPA
    Exec. VP & CFO

    icon

    What is the ALGS stock price today?

    ALGS stock traded closed the last session at $1.21, which is $-0.06 or -4.72% lower than its previous close of $1.27. ALGS's current trading price is 17.48% lower than its 52-week high of $21.90 where as its distance from 52-week low of 1.03% is -94.47%.

    icon

    How many employees does ALGS have?

    Number of ALGS employees currently stands at -. ALGS operates from One Corporate Drive, 2nd Floor, South San Francisco, CA 94080, United States.

    icon

    Link for ALGS official website?

    Official Webiste of $ALGS is: https://www.aligos.com

    icon

    How do I contact ALGS?

    ALGS could be contacted at ALGS operates from One Corporate Drive, 2nd Floor, South San Francisco, CA 94080, United States, or at phone #800 466 6059 and can also be accessed through its website.

    icon

    How many shares of ALGS are traded daily?

    ALGS stock volume for the day was 94,152 shares while in the previous session number of ALGS shares traded was 90,745 . The average number of ALGS shares traded daily for last 3 months was 356.04 Thousands.

    icon

    How much did ALGS change today?

    The percentage change in ALGS stock occurred in the recent session was -4.72% while the dollar amount for the price change in ALGS stock was $-0.06.

    icon

    What price range ALGS stock been trading in?

    In the recent session, the day high for ALGS stock was $1.27 while the low for ALGS stock touched on the day was $1.2.

    icon

    What is the market cap of ALGS currently?

    The market value of ALGS currently stands at 52.83 Million with its latest stock price at $1.21 and 42.51 Million of its shares outstanding.